Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2011; 136(40): 1998-2001
DOI: 10.1055/s-0031-1286379
DOI: 10.1055/s-0031-1286379
Endokrinologie & Diabetes | Commentary
Endokrinologie© Georg Thieme Verlag KG Stuttgart · New York
Neue Entwicklungen bei Nebennierenerkrankungen
Recent advances in adrenal diseasesFurther Information
Publication History
Publication Date:
28 September 2011 (online)

Schlüsselwörter
Nebennierentumore - Inzidentalome - Nebenniereninsuffizienz
Keywords
adrenal tumors - incidentaloma - adrenal insufficiency
Literatur
- 1
Alkatib A A, Cosma M, Elamin M B, Erickson D, Swiglo B A, Erwin P J, Montori V M.
A systematic
review and meta-analysis of randomized placebo-controlled trials
of DHEA treatment effects on quality of life in women with adrenal
insufficiency.
J Clin Endocrinol Metab.
2009;
94
3676-3681
MissingFormLabel
- 2
Barron J.
Phaeochromocytoma: diagnostic challenges for biochemical screening
and diagnosis.
J Clin Pathol.
2010;
63
669-674
MissingFormLabel
- 3
Betz M J, Degenhart C, Fischer E. et al .
Adrenal vein sampling using rapid cortisol
assays in primary aldosteronism is useful in centers with low success
rates.
Eur J Endocrinol.
2011;
165
301-306
MissingFormLabel
- 4
Beuschlein F, Reincke M.
[Every eighth
case of hypertension originates in the adrenal gland. For whom is
it worthwhile to screen for an endocrine cause?].
MMW
Fortschr Med.
2010;
152
30-31
MissingFormLabel
- 5
Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, Quinkler M.
Influence of hydrocortisone dosage scheme on health-related
quality of life in patients with adrenal insufficiency.
Clin
Endocrinol (Oxf).
2010;
72
297-304
MissingFormLabel
- 6
Bornstein S R.
Predisposing factors for adrenal insufficiency.
N
Engl J Med.
2009;
360
2328-2339
MissingFormLabel
- 7
Brix D, Allolio B, Fenske W. et
al .
Laparoscopic versus open adrenalectomy for adrenocortical
carcinoma: surgical and oncologic outcome in 152 patients.
Eur
Urol.
2010;
58
609-615
MissingFormLabel
- 8
Cawood T J, Hunt P J, O’Shea D, Cole D, Soule S.
Recommended evaluation of adrenal incidentalomas is costly,
has high false-positive rates and confers a risk of fatal cancer
that is similar to the risk of the adrenal lesion becoming malignant;
time for a rethink?.
Eur J Endocrinol.
2009;
161
513-527
MissingFormLabel
- 9
Chiodini I.
Clinical review: Diagnosis and treatment of subclinical hypercortisolism.
J Clin Endocrinol Metab.
2011;
96
1223-1236
MissingFormLabel
- 10
Comino-Mendez I, Gracia-Aznarez F J, Schiavi F. et al .
Exome sequencing identifies
MAX mutations as a cause of hereditary pheochromocytoma.
Nat
Genet.
2011;
43
663-667
MissingFormLabel
- 11
de Bruin C, Feelders R A, Lamberts S W, Hofland L J.
Somatostatin
and dopamine receptors as targets for medical treatment of Cushing’s Syndrome.
Rev Endocr Metab Disord.
2009;
10
91-102
MissingFormLabel
- 12
Eisenhofer G, Lenders J W, Timmers H. et al .
Measurements of plasma methoxytyramine, normetanephrine,
and metanephrine as discriminators of different hereditary forms of
pheochromocytoma.
Clin Chem.
2011;
57
411-420
MissingFormLabel
- 13
Fassnacht M, Johanssen S, Quinkler M. et al .
Limited prognostic value of the 2004 International
Union Against Cancer staging classification for adrenocortical carcinoma:
proposal for a Revised TNM Classification.
Cancer.
2009;
115
243-250
MissingFormLabel
- 14
Fassnacht M, Libe R, Kroiss M, Allolio B.
Adrenocortical carcinoma:
a clinician’s update.
Nat Rev Endocrinol.
2011;
7
323-335
MissingFormLabel
- 15
Fischer E, Beuschlein F, Reincke M.
[Diagnosis of endocrinological hypertension: when to screen,
and by which method?].
Dtsch Med Wochenschr.
2011;
136
537-540
MissingFormLabel
- 16
Fischer E, Beuschlein F, Bidlingmaier M, Reincke M.
Commentary on the Endocrine
Society Practice Guidelines: Consequences of adjustment of antihypertensive
medication in screening of primary aldosteronism.
Rev
Endocr Metab Disord.
2011;
12
43-48
MissingFormLabel
- 17
Funder J W, Reincke M.
Aldosterone: a cardiovascular
risk factor?.
Biochim Biophys Acta.
2010;
1802
1188-1192
MissingFormLabel
- 18
Johannsson G, Bergthorsdottir R, Nilsson A G, Lennernas H, Hedner T, Skrtic S.
Improving glucocorticoid
replacement therapy using a novel modified-release hydrocortisone
tablet.
Eur J Endocrinol.
2009;
161
119-130
MissingFormLabel
- 19
Krug A W, Ehrhart-Bornstein M.
Aldosterone and
metabolic syndrome: is increased aldosterone in metabolic syndrome
patients an additional risk factor?.
Hypertension.
2008;
51
1252-1258
MissingFormLabel
- 20
Lovas K, Husebe E S.
Continuous subcutaneous
hydrocortisone infusion in Addison`s disease.
Eur
J Endocrinol.
2007;
157
109-112
MissingFormLabel
- 21
Nieman L K.
Approach to the patient with an adrenal incidentaloma.
J
Clin Endocrinol Metab.
2010;
95
4106-4113
MissingFormLabel
- 22
Petrossians P, Thonnard A S, Beckers A.
Medical treatment in Cushing’s syndrome: dopamine agonists
and cabergoline.
Neuroendocrinology.
2010;
92 Suppl 1
116-119
MissingFormLabel
- 23
Qin Y, Yao L, King E E. et al .
Germline mutations in TMEM127 confer susceptibility
to pheochromocytoma.
Nat Genet.
2010;
42
229-233
MissingFormLabel
- 24
Sbiera S, Schmull S, Assie G. et al .
High diagnostic and prognostic value of
steroidogenic factor-1 expression in adrenal tumors.
J
Clin Endocrinol Metab.
2010;
95
(10)
E161-71
MissingFormLabel
- 25
Verma S, Vanryzin C, Sinaii N. et
al .
A pharmacokinetic and pharmacodynamic study of delayed-
and extended-release hydrocortisone (Chronocort) vs. conventional
hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
Clin Endocrinol (Oxf).
2010;
72
441-447
MissingFormLabel
Dr. Matthias Gruber
Medizinische Klinik und Poliklinik III
Universitätsklinikum Carl
Gustav Carus
der Technischen Universität Dresden
Fetscherstraße 74
01307 Dresden
Email: Matthias.Gruber@uniklinikum-dresden.de